Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial-Reference-Cited by-同舟云学术

Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial

Published:2023-12 Issue: Volume: Page:1-9
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Zheng Zhiwei¹²,Chen Hongcai²³,Cai Hongfu⁴,Xu Siqi¹²

Affiliation:

1. Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Shantou, China

2. Guangdong Provincial Key Laboratory of Breast Cancer Diagnosis and Treatment, Cancer Hospital of Shantou University Medical College, Shantou, China

3. Department of Oncology Medicine, Cancer Hospital of Shantou University Medical College, Shantou, China

4. Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2023.2291157

Reference40 articles.

1. Global trends and forecasts of breast cancer incidence and deaths;Xu Y;Sci Data,2023

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Update on Breast Cancer

4. HER2-positive metastatic breast cancer: a comprehensive review;Exman P;Clin Adv Hematol Oncol,2021

5. Breast cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis;Frontiers in Public Health;2024-07-29